You are viewing an incomplete version of our website. Please click to reload the website as full version.

TNFRSF25 antibody (Tumor Necrosis Factor Receptor Superfamily, Member 25) (Extracellular Domain)

Details for Product anti-TNFRSF25 Antibody No. ABIN1002203, Supplier: Login to see
Antigen
  • TNFRSF25
  • APO-3
  • DDR3
  • DR3
  • LARD
  • TNFRSF12
  • TR3
  • TRAMP
  • WSL-1
  • WSL-LR
  • Tnfrsf12
  • Wsl
Alternatives
anti-Human TNFRSF25 antibody for Western Blotting
Epitope
Extracellular Domain
17
17
15
13
13
10
10
10
5
4
3
3
3
2
2
2
1
1
Reactivity
Human, Mouse (Murine)
171
60
28
2
Host
Rabbit
146
31
4
1
Clonality
Polyclonal
Conjugate
This TNFRSF25 antibody is un-conjugated
10
10
4
4
2
2
2
2
2
2
2
2
2
2
2
Application
Immunocytochemistry (ICC), ELISA, Western Blotting (WB)
124
59
22
22
21
18
10
7
5
2
2
2
1
1
1
Supplier
Login to see
Supplier Product No.
Login to see
Request

Showcase your results, aid the scientific community, and receive a full refund.

Contribute a validation

Learn more

Immunogen Rabbit polyclol DR3 antibody was raised against a peptide corresponding to amino acids in extracellular domain (ED) of human DR3 precusor.
Blocking Peptide Blocking peptide for this product available: ABIN1003922
Isotype IgG
Purification Antibody is purified via DEAE-column chromatography.
Alternative Name Death Receptor 3 (TNFRSF25 Antibody Abstract)
Background Apoptosis, or programmed cell death, occurs during normal cellular differentiation and development of multicellular organisms. Apoptosis is induced by certain cytokines including TNF and Fas ligand of the TNF family through their death domain containing receptors, TNFR1 and Fas. A novel cell death receptor was recently identified by several groups independently and designated DR3, Wsl-1, Apo-3, TRAMP and LARD1-5. The ligand for this novel death receptor has been defined as TWEAK, also termed Apo3L. DR3 is highly expressed in the tissues enriched in lymphocytes including PBL, thymus and spleen. Like TNFR1, DR3 induces apoptosis and NF-kappaB activation.
Pathways Apoptosis
Application Notes DR3 antibody can be used for detection of DR3 expression by Western blot at 1 – 2 µg/ml. (Optimal dilution should be determined by user.) Jurkat total cell lysate can be used as positive control and a 59 kDa band should be detected. Antibody can also be used for immunocytochemistry and ELISA and might be suited for other applications not tested so far. DR3 antibody is human and mouse reactive.
Restrictions For Research Use only
Format Liquid
Buffer Antibody is supplied in PBS containing 0.02% sodium azide.
Preservative Sodium azide
Precaution of Use This product contains sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
Handling Advice Antibody can be stored at 4ºC, stable for one year. As with all antibodies care should be taken to avoid repeated freeze thaw cycles. Antibodies should not be exposed to prolonged high temperatures. During shipment, small volumes of antibody will occasionally become entrapped in the seal of the product vial. For products with volumes of 200 myl or less, we recommend gently tapping the vial on a hard surface or briefly centrifuging the vial in a tabletop centrifuge to dislodge any liquid in the container’s cap.
Storage 4 °C
Expiry Date 12 months
Product cited in: Bodmer, Burns, Schneider et al.: "TRAMP, a novel apoptosis-mediating receptor with sequence homology to tumor necrosis factor receptor 1 and Fas(Apo-1/CD95)." in: Immunity, Vol. 6, Issue 1, pp. 79-88, 1997 (PubMed).

Marsters, Sheridan, Donahue et al.: "Apo-3, a new member of the tumor necrosis factor receptor family, contains a death domain and activates apoptosis and NF-kappa B." in: Current biology : CB, Vol. 6, Issue 12, pp. 1669-76, 1997 (PubMed).

Background publications Kitson, Raven, Jiang et al.: "A death-domain-containing receptor that mediates apoptosis." in: Nature, Vol. 384, Issue 6607, pp. 372-5, 1996 (PubMed).

Chinnaiyan, ORourke, Yu et al.: "Signal transduction by DR3, a death domain-containing receptor related to TNFR-1 and CD95." in: Science (New York, N.Y.), Vol. 274, Issue 5289, pp. 990-2, 1996 (PubMed).